Chronic myelomonocytic leukemia
Citation, DOI, disclosures and article data
At the time the article was created Yuranga Weerakkody had no recorded disclosures.View Yuranga Weerakkody's current disclosures
At the time the article was last revised Yuranga Weerakkody had no recorded disclosures.View Yuranga Weerakkody's current disclosures
Chronic myelomonocytic leukemia (CMML) is a relatively rare clonal hematologic disorder. In the World Health Organizatiοn classification, it is listed as a disorder with features of both myelodysplastic syndromes and myeloproliferative neoplasms.
It is usually characterized by accumulation of monocytes in the blood and bone marrow, dysplastic hematopoiesis.
The diagnosis is characterized by:
- peripheral monocytosis (>1x109/L)
- absence of Philadelphia chromosome and BCR/ABL fusion gene
- fewer than 20% lymphoblasts in the blood or bone marrow
- dysplasia involving one or more myeloid lineages
Two types of CMML have been described.
- type 1: has less than 5% blasts (immature blood cells)
- type 2: has between 5-20% blasts in the blood
Treatment and prognosis
The clinical course is variable. There is potential for leukemic involvement of organs. Blood transfusions and erythropoietin (EPO) administration may play a role in correcting low hemoglobin levels in cases with anemia.
- 1. Hyams ES, Gupta R, Melamed J et-al. Renal involvement by chronic myelomonocytic leukemia requiring nephroureterectomy. Rev Urol. 2011;11 (1): 33-7. Free text at pubmed - Pubmed citation
- 2. Michaux JL, Martiat P. Chronic myelomonocytic leukaemia (CMML)-a myelodysplastic or myeloproliferative syndrome?. Leuk. Lymphoma. 2015;9 (1-2): 35-41. doi:10.3109/10428199309148501 - Pubmed citation
- 3. Derlin T, Clauditz TS, Bannas P. 18F-FDG PET/CT for staging and detection of extramedullary organ involvement in chronic myelomonocytic leukemia. Clin Nucl Med. 2014;39 (9): 811-2. doi:10.1097/RLU.0b013e3182a77c99 - Pubmed citation